Naar de inhoud
SLETOR
OpenSubsidieMedische apparatuur en farmacie

Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses[E8]

UnknownEuropean Commission[E1]

Sluit[E2]
Deadline van de financier: 17 feb 2027, 01:00 Midden-Europese tijd (UTC+1). UTC: 17 feb 2027, 00:00 UTC.
Totale financiering[E9]
EUR 11.000.000
Taal van de inschrijving
Jouw taal
Log in om deze inschrijving te volgenDeadline aan agenda toevoegen
Pagina van de financier (opent in een nieuw tabblad)

In gewone taal

Wat het financiert
Korte samenvatting in jouw taal wordt geschreven…
Wie kan aanvragen
  • EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.
  • Open voor: Universities and research
  • Fase: Prototype and MVP
Handleiding en aanvraag

De handleiding, regels en het aanvraagformulier staan op de pagina van de financier. Lees ze voordat u aanvraagt.

Risico's en onbekenden

  • RisicoThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
  • OnbekendWe read the funder's listing, not the full guidance or application forms.
Opent[E6]
29 okt 2026
Bron
EU Funding & Tenders Portal (grants and calls for proposals) (opent in nieuw tabblad)
Laatst gecontroleerd
11 uur geleden
Over de financiering · Uit de aankondiging
Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to experimental monoclonal antibodies for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. Candidate monoclonal antibody therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope: Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The capacity to produce antibodies that can target new variants and rapidly increase production would serve as an essential preparedness strategy against future health threats, whether from infectious disease epidemics or pandemics. This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the imp…[E3]

Wie kan aanvragen

  • Open voorUniversities and research. Door SLETOR ingedeeld op basis van de woorden in de vermelding.
  • VoorwaardeEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

Financier

Wat deze financier nog meer aanbiedt

European Commission

De oproep geeft geen andere contactroute dan de oorspronkelijke pagina.

Zo stelt u een vraag

Stel vragen via de pagina of het contactpunt van de financier. Lees eerst de handleiding. Open de route van de dienst

Wij tonen alleen de gepubliceerde contactroute van de organisatie: website, platform, algemene mailboxen en algemene nummers. Nooit een persoon.

Bewijs9 feiten uit de aankondiging · Tonen

Elk gegeven op deze pagina komt uit de vermelding van de financier. Elke regel toont het record en het veld waaruit het is gelezen.

  1. E1

    The funder is European Commission.

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/type/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

  2. E2

    Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

    “2027-02-17T00:00:00.000+0000”

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/deadlineDate/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

  3. E3

    The buyer describes the requirement in the notice.

    “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed…”

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/descriptionByte/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

  4. E4

    EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

    “EU call topic”

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/type/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

  5. E5

    This is an EU call for proposals.

    “31094502”

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/status/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

  6. E6

    Applications open on 29 Oct 2026.

    “2026-10-29T00:00:00.000+0000”

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/startDate/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

  7. E7

    The Funding & Tenders Portal gives the status as open for submission.

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/status/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

  8. E8

    The notice is titled "Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses".

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/title/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

  9. E9

    The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

    Uit Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07), veld /metadata/budgetOverview/0, gelezen 29 okt 2026, 07:41 UTC · bron (opent in nieuw tabblad)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Datalicentie: Creative Commons Attribution 4.0 (European Commission) (opent in nieuw tabblad). Persoonlijke contactgegevens uit aankondigingen worden niet bewaard of getoond.

Updates

  1. Open voor inschrijving · 29 okt 2026, 07:41 UTC

    The funder published the call with a future closing date.

    Gewijzigd: status, notice type, published at (bronrecord Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07))

  2. Voor het eerst gezien · 28 okt 2026, 21:22 UTC

    The funder announced the call. Applications have not opened yet.

    Bronrecord: Development of monoclonal antibodies to prevent and treat infections from Filo-… (ID HORIZON-HLTH-2027-01-DISEASE-07)